EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Survey of Didemnin Depsipeptide Production in Tistrella

Robert J Stankey iD, Don Johnson, Brendan M Duggan iD, David A Mead iD, James J La Clair iD

Marine Drugs · 2023

DOI: 10.3390/md21020056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, 2023. Verfasst von Robert J Stankey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Terra Bioworks Inc., Middleton, WI 53562, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Depsipeptides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xenobe Research Institute, Terra Bioworks.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family Didemnidae, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria Tistrella mobilis. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in Tistrella currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of Tistrella and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDepsipeptidesPeptides, Cyclic

Stichwörter der Autor:innen

biosynthesisdepsipeptidedidemninmetabolomicsnon–ribosomal peptide

Substanzen

didemninsAntineoplastic AgentsDepsipeptidesPeptides, Cyclic

Autor:innen und Institutionen

  • Terra Bioworks Inc., Middleton, WI 53562, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, San Diego, CA 92093-0657, USA.
  • Department of Chemistry and Biochemistry, University of California, San Diego, CA 92093-0358, USA.
  • Xenobe Research Institute, P.O. Box 3052, San Diego, CA 92163-1052, USA.

ORCID-Profile: Robert J Stankey, Brendan M Duggan, David A Mead, James J La Clair

Förderung

  • Xenobe Research Institute
  • Terra Bioworks

Zitieren

APA

Stankey, R. J., Johnson, D., Duggan, B. M., Mead, D. A., & La Clair, J. J. (2023). A Survey of Didemnin Depsipeptide Production in Tistrella. Marine Drugs. https://doi.org/10.3390/md21020056

Vancouver

Stankey RJ, Johnson D, Duggan BM, Mead DA, La Clair JJ. A Survey of Didemnin Depsipeptide Production in Tistrella. Marine Drugs. 2023. doi:10.3390/md21020056

BibTeX
@article{Stankey2023,
  author = {Stankey, Robert J and Johnson, Don and Duggan, Brendan M and Mead, David A and La Clair, James J},
  title = {A Survey of Didemnin Depsipeptide Production in Tistrella},
  journal = {Marine Drugs},
  year = {2023},
  doi = {10.3390/md21020056}
}
Kostenlos starten →